The Value of Serum MicroRNA-21-5p and LncRNAgadd7 Expression Levels in Predicting the Severity and Prognosis of ARDS ( Acute Respiratory Distress Syndrome )

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06825754

Enrollment

110

Registered

2025-02-13

Start date

2023-11-01

Completion date

2025-01-10

Last updated

2025-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Brief summary

By measuring the expression levels of MicroRNA-21-5p (miR-21-5p) and LncRNAgadd7 in the peripheral blood of ARDS patients, the study aims to explore the correlation between these levels and the severity and prognosis of ARDS.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age ≥ 18 years; 2. Meets the Berlin Criteria for ARDS; 3. Diagnosed with ARDS within 48 hours; 4. Signed informed consent.

Exclusion criteria

1. Immunosuppressed patients: including those on immunosuppressive drugs, history of stem cell transplantation, etc.; 2. Patients with malignant tumors; 3. Pregnant women; 4. Patients discharged from the ICU within 48 hours; 5. History of chronic lung diseases.

Design outcomes

Primary

Measure	Time frame
The expression levels of MicroRNA-21-5p (miR-21-5p)	28 days
the expression levels of LncRNAgadd7	28 days

Countries

China

Outcome results